Aryabhatta Sadhu: Which Part of Haemostasis Has Failed First?
Aryabhatta Sadhu, Attending Consultant and Head of Transfusion Medicine at Fortis Hospital Shalimar Bagh, New Delhi, shared a post on LinkedIn:
“A bleeding patient with ‘acceptable’ platelets can still be haemostatically unsafe.
One common error in active bleeding is looking at haemoglobin and platelet count first, while fibrinogen is checked late – or corrected even later.
That is backwards physiology.
In major bleeding, fibrinogen is often one of the earliest haemostatic factors to fall.0
A patient may have a platelet count of 70,000–90,000/µL and still continue bleeding because the clot being formed has poor fibrin strength.
The clinical decision point is simple:
Before reflexively asking for ‘2 FFP and 1 platelet,’ ask:
What is the fibrinogen?
If the patient is actively bleeding and fibrinogen is low, correction with cryoprecipitate or fibrinogen concentrate should be considered early, depending on local availability and protocol.
This is even more critical in obstetric haemorrhage, trauma, liver disease, cardiac surgery, DIC-like states, and massive transfusion scenarios.
Platelets are not cement by themselves.
FFP is not a universal correction fluid.
Cryoprecipitate is not a ‘last step’ component.
A bleeding patient needs haemostatic reconstruction: red cells for oxygen carriage, plasma factors when coagulation is globally impaired, platelets when primary haemostasis is inadequate, fibrinogen when clot strength is failing, calcium when citrate load rises, and temperature/pH correction because enzymes do not work in a hostile physiology.
Practical takeaway:
In active bleeding, do not treat the CBC alone.
Ask for:
- PT/INR
- aPTT
- fibrinogen
- platelet count
- ionised calcium
- ABG/lactate
- TEG/ROTEM if available
The question is not ‘Which blood component is pending?’
The question is:
Which part of haemostasis has failed first?
That is where Transfusion Medicine must move beyond blood issue and function as bedside haemotherapy consultation.”

Other posts featuring Aryabhatta Sadhu with Hemsotasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering